<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
Amendment No. 1
------------
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended October 31, 1999 Commission file number: 0-22354
MARTEK BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
------------
DELAWARE 52-1399362
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
6480 DOBBIN ROAD, COLUMBIA, MARYLAND 21045
(Address of principal executive offices)
REGISTRANT'S TELEPHONE NUMBER INCLUDING AREA CODE: (410) 740-0081
------------
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
None None
(Title of class:) (Name of each exchange on which registered:)
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
Common Stock, $.10 par value
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the last 90 days. X Yes No
--- ---
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
The aggregate market value of Common Stock held by non-affiliates of
registrant is $161,449,892 (based upon a last sale price of $12.0625 per share
of the Common Stock as reported on the NASDAQ National Market System on January
14, 2000). The number of shares of Common Stock outstanding as of January 14,
2000 was 16,517,364.
DOCUMENTS INCORPORATED BY REFERENCE
None
<PAGE> 2
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The directors and executive officers and key employees of the Company are
as follows:
<TABLE>
<CAPTION>
NAME AGE POSITION
----------------------------------- --- ------------------------------------------------
<S> <C> <C>
Henry Linsert, Jr....................... 59 Chairman, Chief Executive Officer and Director
Richard J. Radmer, Ph.D................. 57 President, Chief Scientific Officer and Director
Thomas C. Fisher........................ 53 Senior Vice President, Operations
David J. Kyle, Ph.D..................... 46 Senior Vice President, Research and Development
Jerome C. Keller........................ 57 Senior Vice President, Sales & Marketing
Steve Dubin............................. 46 Senior Vice President, Business Development,
General Counsel, and Secretary
Peter L. Buzy........................... 40 Chief Financial Officer and Treasurer
Paul W. Behrens, Ph.D................... 43 Director of Physiology
Jonathan Miles Brown, Ph.D.............. 44 Director, Stable Isotope Group
Paul J. Kelley.......................... 46 Vice President of Manufacturing
Gordon S. Macklin....................... 71 Director
William D. Smart........................ 73 Director
Jules Blake............................. 75 Director
Ann L. Johnson, M.D..................... 63 Director
Sandra Panem, Ph.D...................... 53 Director
Douglas J. MacMaster.................... 69 Director
John H. Mahar........................... 65 Director
Eugene H. Rotberg....................... 70 Director
</TABLE>
Henry Linsert, Jr. joined Martek as Chairman of the Board in 1988 and
became Chief Executive Officer in 1989. From 1987 to 1988 he was primarily
engaged as President of American Technology Investments Corp. ("ATI"), a
consulting company specializing in the development and financing of early stage
companies in the Mid-Atlantic area. He was President and Chief Executive Officer
of Suburban Capital Corporation, a venture capital subsidiary of Sovran
Financial Corporation (now Bank of America), from 1983 to 1987. Prior to 1983,
Mr. Linsert was Vice President of Inverness Capital Corporation, a small
business investment company, and Vice President of First Virginia Bank. He also
served as a Captain in the U.S. Marine Corps and as an artillery officer in
Vietnam. He received an M.A. in economics from George Washington University and
a B.A. from Duke University. His term as director expires 2002.
Dr. Richard J. Radmer, a founder of Martek, has served since 1985 as a
director and as President and Chief Scientific Officer of the Company. Prior to
1985, he worked for 17 years at Martin Marietta Corp. where he headed the
Biosciences Department which performed research to develop new products from
microalgae, among other activities. He has served as an Adjunct Associate
Professor and Associate Member of the Graduate Faculty at the University of
Maryland. Dr. Radmer received a Ph.D. in biology, an M.S. in botany and a B.S.
in biochemistry from the University of Chicago. He completed his Ph.D. studies
while in residence at Harvard University. His term as director expires 2003.
Thomas C. Fisher joined Martek in 1991 and was named Senior Vice
President of Operations in 1992 after 18 years with Merck & Co., Inc. ("Merck")
and Dupont-Merck. Mr. Fisher's last position was Vice President for Technical
Operations at Dupont-Merck, and in that capacity he was responsible for
world-wide pharmaceutical production, quality control and engineering. During
his tenure at Merck, Mr. Fisher was Director of Biological Manufacturing and
held management positions in sterile operations, development and quality
control. Mr. Fisher received an M.S. in genetics from West Virginia University
and a B.S. in biology from Waynesburg College.
Dr. David J. Kyle, a founder of Martek, is currently Senior Vice
President, Head of Research and Development. Prior to co-founding Martek in
1985, Dr. Kyle was a research scientist in the Biosciences Department at Martin
<PAGE> 3
Marietta Corp. from 1984 to 1985. He has been a post-doctoral fellow at Michigan
State University and a visiting scientist at the Centre d'Etudes Nucleaires of
Saclay, France, and the Institute of Physical and Chemical Research, Tokyo,
Japan. Dr. Kyle received a Ph.D. in physiology and biochemistry from the
University of Alberta, and a B.S. degree in biology from the University of
Victoria.
Jerome C. Keller joined Martek in September 1997 as Senior Vice President
of Sales and Marketing. Prior to joining Martek, Mr. Keller had been consulting
after spending a 25-year career at Merck, most recently as Vice President of
Sales from 1986 to 1993. In this position, he was responsible for all U.S. sales
operations, including the direction of a support staff of 4,500 personnel and a
sales volume of $4.2 billion. Some of the products introduced under Mr. Keller
included Pepcid, Mefoxin, Primaxin, Vasotec, Mevocor, Zocor, Proscor and
Prilosec. Mr. Keller has a M.S. degree from the University of Pittsburgh and a
B.S. degree from Duquesne University.
Steve Dubin is currently Senior Vice President of Business Development,
General Counsel and Secretary. Mr. Dubin joined Martek in 1992 as Chief
Financial Officer and from 1988 to the time he joined Martek on a full-time
basis, Mr. Dubin consulted with the Company on financial and accounting matters.
Prior to joining Martek, Mr. Dubin was Chief Financial Officer of the J.L.
Wickham Co., Inc., a machine tool company, from 1987 to 1992. From 1986 to 1991,
Mr. Dubin was active as Vice President of ATI, a consulting company of which Mr.
Dubin was a co-founder, specializing in the development and financing of early
stage companies in the Mid-Atlantic area. Prior to 1986, he served as Vice
President of Suburban Capital Corporation, a venture capital subsidiary of
Sovran Financial Corporation (now Bank of America), where he participated in the
original financing of the Company. Mr. Dubin also held a variety of financial
management positions with Suburban Bank. Mr. Dubin is a Certified Public
Accountant and an attorney. He received his J.D. from the National Law Center,
George Washington University and his B.S. in accounting from the University of
Maryland.
Peter L. Buzy joined Martek in March 1998 as Chief Financial Officer.
Prior to joining Martek, Mr. Buzy spent 13 years with the accounting and
consulting firm of Ernst & Young LLP, most recently as an audit partner in the
Northern Virginia High Technology/Life Sciences Practice. Mr. Buzy was a member
of the Ernst & Young audit team servicing Martek from 1986 - 1996, and as such
has played a vital role in advising the Company on various technical accounting
and finance related issues. Mr. Buzy is a Certified Public Accountant and a
member of the American Institute of Certified Public Accountants. He received
his B.S. in accounting from Salisbury State University.
Dr. Paul W. Behrens, a founder of Martek, has served as Director of
Physiology since 1985 and is responsible for the Company's microalgal-screening
activity, aquaculture product development and microalgal-physiology expertise.
Prior to joining Martek, Dr. Behrens was a research scientist in the Biosciences
Department at Martin Marietta Corp. from 1983 to 1985. He received a Ph.D. in
physiology and biochemistry and a M.S. in biology from the University of
Maryland. He also received a B.A. in biology from The Johns Hopkins University.
Dr. Jonathan Miles Brown, who is overseeing the development of Martek's
Stable Isotope products, joined Martek in September 1991 following a period as a
consultant with British Biotechnology Ltd. Prior thereto, he was Research and
Development Manager for Oxford Virology plc from 1987 to 1990 where his
responsibilities included market research, preparation of all marketing
documents and protection of intellectual property. Dr. Brown received his Ph.D.
from the University of London where he developed the first synthetic process for
the unambiguous synthesis of long chain oligoribonucleotides. He is a Chartered
Chemist and Member of the Royal Society of Chemistry.
<PAGE> 4
Paul J. Kelley joined Martek in April 1997 as Vice President of
Manufacturing at the Company's Winchester, Kentucky production plant. Prior to
joining Martek, Mr. Kelley spent four years as the Plant Manager of a
Biotechnology plant in the Pharmaceutical Division of Bayer. Prior to 1993, Mr.
Kelley held several other positions at Bayer, including Production Manager of a
plant in West Germany from 1989 to 1991. Prior to working for Bayer, Mr. Kelley
was the Plant Manager of a facility in the Biotechnology Division of Miles, Inc.
from 1983 to 1989. Mr. Kelley received an M.B.A. from Rutgers Graduate School of
Business and a B.S.C.E. from the New Jersey Institute of Technology.
Gordon S. Macklin is a director of the Company and a member of its Audit
Committee. Mr. Macklin serves as a director for White Mountains Insurance Group,
LTD, MCI WorldCom., MedImmune, Inc. (biotechnology), Spacehab, Inc. (aerospace
technology)and director, trustee, managing general partner, as the case may be,
for 47 of the investment companies in the Franklin Templeton Group of Funds;
formerly Chairman, White River Corporation (financial services)(until 1998),
Chairman, Hambrecht and Quist Group (financial services)(until 1992), and
President, National Association of Securities Dealers, Inc. (until 1987). Mr.
Macklin has been a director of the Corporation since November, 1998. His term
expires in 2003.
William D. Smart is a director of the Company and a member of its
Compensation Committee. From 1955 until his retirement in 1987, Mr. Smart served
in a variety of capacities for Abbott Laboratories, a pharmaceutical and
healthcare company, most recently as President of Ross Laboratories, the
nutritional products division of Abbott Laboratories, and Corporate Vice
President of Abbott Laboratories. Mr. Smart has been a director of the
Corporation since 1991. His term expires in 2003.
Jules Blake, Ph.D. is a director of the Company and a member of its Audit
Committee. Dr. Blake served as Vice President of Research and Development, and
later Vice President, Corporate Scientific Affairs, for Colgate-Palmolive from
1973 until 1989. Following his retirement in 1989, Dr. Blake accepted an
appointment as Industrial Research Institute Fellow at the Office of Science and
Technology Policy, Executive Office of the President, where he served until
1991. Dr. Blake also serves as a director for Gene Logic, Inc. and Procyte
Corporation. Dr. Blake has been a director of the Corporation since 1990. His
term expires in 2002.
Ann L. Johnson, M.D. is a director of the Company and a member of its
Compensation Committee. Dr. Johnson has served as a physician on the neonatology
staff of Mills Peninsula Hospital since 1992. Dr. Johnson has a private practice
in psychiatry and psychopharmacology. Dr. Johnson has been a director of the
Company since March 1995. Her term expires in 2002.
Sandra Panem, Ph.D. is a director of the Company and a member of its
Audit Committee. Dr. Panem is the former President of Vector Fund Management,
L.P. ("VFM") and was responsible for running the day-to-day operations for the
Vector Later-Stage Equity Fund, L.P. and Vector Later-Stage Equity Fund II, L.P.
which focused on later-stage companies. Prior to joining VFM, she served as Vice
President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a
mutual fund that invested in public and private biotechnology companies. Prior
to joining Oppenheimer, Dr. Panem was a Vice President at Salomon Brothers
Venture Capital, a fund focused on early and later-stage life sciences and
technology investments. Dr. Panem has been a director of the Company since May
1995. Prior to that time, she served as a director from June 1990 until February
1993. Dr. Panem also serves as a director for StressGen Technologies, Inc. and
Synaptic Pharmaceutical Corporation. Her term expires in 2002.
<PAGE> 5
Douglas J. MacMaster, Jr. is a director of the Company and a member of
its Compensation Committee. Mr. MacMaster served in various management positions
at Merck & Co., Inc. from 1961 to 1988, at which time he was appointed Senior
Vice President responsible for ten divisions, including Manufacturing and
Technology, and Pharmaceutical Manufacturing. Mr. MacMaster retired from Merck
in 1991 and currently serves as a director for American Precision Industries,
Inc., Neose Technologies, Inc. and Stratton Mutual Funds. Mr. MacMaster has been
a director of the Corporation since 1993. His term expires in 2001.
John H. Mahar is a director of the Company and a member of its
Compensation Committee. Mr. Mahar has served as President of Hillside
Management, a consulting firm, since 1992. From 1991 to 1992, Mr. Mahar was a
Vice President at Salomon Brothers Inc. serving as a principal for the Venture
Capital Fund. From 1985 to 1991, Mr. Mahar was Executive Vice President and
Chief Operating Officer of Elf Technologies, Inc., a venture capital firm. Mr.
Mahar was reelected as a director of the Corporation in February 1993. Prior to
that time, he served as a director of the Corporation from 1988 until 1991. His
term expires in 2001.
Eugene H. Rotberg is a director of the Company and a member of its Audit
Committee. Since 1990, Mr. Rotberg has been an independent advisor to
international development and financial institutions. From 1987 to 1990, Mr.
Rotberg was Executive Vice President and a member of the Executive Committee at
Merrill Lynch & Co., Inc. From 1969 to 1987, Mr. Rotberg was Vice President and
Treasurer of the World Bank. Mr. Rotberg has been a director of the Corporation
since 1992. His term expires in 2001.
DIRECTORS' FEES
Each director who is not an employee of the Corporation receives an
annual retainer of $10,000, plus expenses. These directors are also eligible to
receive options under the Company's 1986 Stock Option Plan, as amended and
restated in 1992, and the Company's 1997 Stock Option Plan (collectively the
"Option Plan"). Currently, each eligible director receives each year options to
purchase 10,000 shares of stock on the day of the Corporation's Annual Meeting
of Stockholders, provided he or she has served as a Director of the Corporation
for at least one year as of such Annual Meeting of Stockholders or otherwise has
received Board approval for the grant. In addition, each newly elected director
receives options to purchase 10,000 shares of the Corporation's Common Stock
upon joining the Board. Directors may also be compensated for special
assignments delegated by the Board. In the year ended October 31, 1999 each
director, other than Mr. Linsert and Dr. Radmer, received options resulting from
their service as a Director to purchase 10,000 shares at $6.25 per share under
the Option Plan. All option grants to Directors are granted at the closing price
for the Corporation's Common Stock as reported on the NASDAQ Stock Market on the
day prior to the date of grant.
SECTION 16 (a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
The Securities Exchange Act of 1934 requires the Corporation's directors,
executive officers and 10% stockholders to file reports of ownership of equity
securities of the Corporation and to furnish copies of such reports to the
Corporation. Based on a review of such reports, the Corporation believes that,
during the fiscal year ended October 31, 1999, all such filing requirements were
met.
<PAGE> 6
ITEM 11. EXECUTIVE COMPENSATION.
EXECUTIVE COMPENSATION
The table below sets forth the annual and long-term compensation for
services in all capacities to the Corporation for the fiscal years ended October
31, 1999, 1998 and 1997 of (i) the Chief Executive Officer and (ii) the five
other most highly compensated executive officers of the Corporation whose salary
and bonus exceeded $100,000 (the "Named Executive Officers").
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM COMPENSATION
----------------------
ANNUAL COMPENSATION AWARDS
------------------- ------
NAME AND
PRINCIPAL SECURITIES UNDERLYING ALL OTHER
POSITION YEAR SALARY ($) BONUS ($) (1) OPTIONS (#) COMPENSATION ($)
- -------- ---- ---------- ------------- ----------- ----------------
<S> <C> <C> <C> <C> <C>
Henry Linsert, Jr., 1999 235,000 32,900 210,000 --
Chief Executive 1998 230,875 -- 30,000 --
Officer 1997 217,500 -- 50,000 --
David J. Kyle, 1999 157,000 21,980 67,750 --
Sr. Vice President, 1998 154,375 -- 20,000 --
Research and 1997 145,833 -- 40,000 --
Development
Thomas C. Fisher, 1999 152,000 21,280 90,000 3,198 (2)
Sr. Vice 1998 149,375 -- 20,000 5,167 (2)
President, Operations 1997 142,500 -- 40,000 3,900 (2)
Steve Dubin, 1999 152,000 21,280 65,000 --
Sr. Vice President, 1998 147,250 -- 20,000 --
Business Development, 1997 130,500 -- 40,000 --
General Counsel,
and Secretary
Jerome C. Keller, 1999 152,000 21,280 40,000 --
Sr. Vice President, 1998 140,000 -- 20,000 --
Sales and 1997 11,846 -- 150,000 --
Marketing (3)
Peter L. Buzy, 1999 147,500 21,280 40,000 --
Chief Financial 1998 96,833 -- 50,000 55,348 (5)
Officer (4)
</TABLE>
- ------------------
(1) All Named Executive Officers received bonuses based on performance in
fiscal 1999 pursuant to the Corporation's Management Cash Bonus Incentive
Plan (the "Bonus Plan"). See the Report on Executive Compensation below
for a description of the Bonus Plan.
(2) Consists of payments to Mr. Fisher to cover certain commuting expenses.
(3) Mr. Keller joined the Corporation in September, 1997.
(4) Mr. Buzy joined the Corporation in March, 1998.
(5) Consists of payments to Mr. Buzy to cover certain moving expenses.
<PAGE> 7
OPTION GRANTS IN LAST FISCAL YEAR
Shown below is information on grants to the Corporation's Chief Executive
Officer and the Named Executive Officers of stock options pursuant to the Option
Plan during the year ended October 31, 1999.
<TABLE>
<CAPTION>
POTENTIAL REALIZABLE VALUE
AT ASSUMED ANNUAL RATES
OF STOCK PRICE APPRECIATION
INDIVIDUAL GRANTS FOR OPTION TERM (3)
---------------------------------------------------------------------- --------------------------------
PERCENTAGE OF
NUMBER OF TOTAL OPTIONS
SECURITIES GRANTED TO EXERCISE OR
UNDERLYING EMPLOYEES IN BASE PRICE EXPIRATION
NAME OPTIONS GRANTED (#)(1) FISCAL YEAR 1999 ($/SH) (2) DATE 5% ($) 10% ($)
- ------------------ ---------------------- ---------------- ----------- ---------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Henry Linsert, Jr. 210,000 24.4 6.25 3/11/09 825,424 2,091,787
Thomas C. Fisher 90,000 10.5 6.25 3/11/09 353,753 896,480
David J. Kyle 67,750 7.9 6.25 3/11/09 266,298 674,850
Steve Dubin 65,000 7.6 6.25 3/11/09 255,488 674,458
Jerome C. Keller 40,000 4.7 6.25 3/11/09 157,224 398,436
Peter L. Buzy 40,000 4.7 6.25 3/11/09 157,224 398,436
</TABLE>
- ----------------
(1) Options become exercisable ratably beginning six months from the date of
grant through four years from the date of grant.
(2) Options were granted at the market price on the date of grant.
(3) The dollar amounts set forth under these columns are the result of
calculations of assumed annual rates of stock price increases from the
respective dates of grant in fiscal 1999 to the respective dates of
expiration of such options in 2009 of 5% and 10%. These assumptions are
not intended to forecast future price appreciation of the Corporation's
stock price. The Corporation's stock price may increase or decrease in
value over the time period set forth above.
OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION VALUES
Shown below is information with respect to the exercise of options to
purchase the Corporation's Common Stock during fiscal 1999 under the Option Plan
and unexercised options held under the Option Plan on October 31, 1999.
<TABLE>
<CAPTION>
NUMBER OF
SECURITIES UNDERLYING VALUE OF UNEXERCISED
UNEXERCISED OPTIONS IN-THE-MONEY OPTIONS
HELD AT OCTOBER 31, 1999(#) AT OCTOBER 31, 1999($)(1)
-------------------------------- -------------------------------
SHARES
ACQUIRED VALUE
NAME ON EXERCISE(#) REALIZED($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ---- -------------- ----------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Henry Linsert, Jr. -- -- 176,000 214,000 78,750 315,000
Thomas C. Fisher -- -- 110,000 105,000 33,750 135,000
David J. Kyle 25,000 17,188 95,550 87,200 25,406 101,625
Steve Dubin -- -- 95,000 85,000 24,375 97,500
Jerome C. Keller -- -- 166,000 44,000 15,000 60,000
Peter L. Buzy -- -- 28,000 62,000 15,000 60,000
</TABLE>
- --------------------
(1) Total value of unexercised options is based on the closing price of the
Corporation's Common Stock of $8.125 per share on October 31, 1999.
EMPLOYMENT AGREEMENTS
The Company entered into employment agreements with Mr. Linsert, Dr.
Radmer and Dr. Kyle in May 1990. The agreement with Mr. Linsert provides for an
annual salary of $120,000, which is subject to normal periodic review. In 1998,
the Board of Directors voted to increase Mr. Linsert's base annual salary to
$235,000. This agreement does not have a fixed term but can be terminated with
six months written notice by either Mr. Linsert or the Company. This agreement
also prohibits Mr. Linsert from engaging in activities competitive with those of
the Company during the period of Mr. Linsert's employment and for one year after
leaving the employ of the Company. The agreements with Drs. Radmer and Kyle
initially provided for an annual salary of $86,000 and $55,000, respectively,
subject to normal yearly adjustments. These agreements provide for a two-year
initial term with respect to Dr. Radmer and a one-year initial term for Dr. Kyle
which are extended automatically for successive one year periods and can be
terminated upon six months written notice given prior to the end of such
successive one year periods by either the Corporation or Drs. Radmer and Kyle,
respectively. In 1998, the Board voted to increase both Dr. Kyle's and Dr.
Radmer's base annual salary to $157,000. In March 1998, the Company entered into
an employment agreement with Mr. Buzy that provides for an annual salary of
$140,000 and includes a relocation reimbursement of up to
<PAGE> 8
$65,000. The agreement has a three year term, provides for normal periodic
reviews and includes a severance fee of up to eighteen months salary. The
agreement provides for a reduction of the severance fee by one twelfth for each
month that Mr. Buzy's length of employment exceeds twenty four months. In March,
1999, the Board voted to increase Mr. Buzy's salary to $152,000.
COMPENSATION COMMITTEE INTERLOCK AND INSIDER PARTICIPATION IN COMPENSATION
DECISIONS
During 1999, Ann L. Johnson, M.D., Douglas J. MacMaster, Jr., John H.
Mahar and William D. Smart served as members of the Compensation Committee. No
director or executive officer of the Company is a director or executive officer
of any other corporation that has a director or executive officer who is also a
director or a board committee member of the Company.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
BENEFICIAL OWNERSHIP OF COMMON STOCK
The following table and footnotes thereto set forth certain information
as of January 20, 2000 (unless otherwise specified) with respect to the
beneficial ownership of the Corporation's Common Stock of each person who is
known by the Corporation to own beneficially more than 5% of the outstanding
shares of Common Stock, each director and nominee, each Named Executive Officer
(as defined above), and all directors and executive officers as a group:
<TABLE>
<CAPTION>
NAME AND ADDRESS OF SHARES BENEFICIALLY
BENEFICIAL OWNERS OWNED (1) PERCENTAGE OF CLASS
- ------------------- ------------------- -------------------
<S> <C> <C>
State of Wisconsin Investment Board
121 East Wilson Street
Madison, WI 53707............................................... 2,227,612 (2) 13.38%
Bank America Corporation
100 North Tryon Street
Charlotte, NC 28255............................................. 1,531,879 (3) 9.27%
The College Retirement Equities Fund
730 Third Avenue
New York, NY 10017.............................................. 1,283,650 7.77%
Eastbourne Capital Management, L.L.C.
1101 Fifth Avenue, Suite 160
San Rafael, California 94901.................................... 1,199,861 (4) 7.21%
George W. Haywood
642 Second Street
Brooklyn, New York 11215........................................ 1,107,584 (5) 6.67%
Henry Linsert, Jr................................................. 467,290 (6) 2.79%
Richard J. Radmer, Ph.D........................................... 520,000 (7) 3.13%
Steve Dubin....................................................... 198,500 (8) 1.19%
David J. Kyle, Ph.D............................................... 253,165 (9) 1.52%
Thomas C. Fisher.................................................. 203,505 (10) 1.19%
Jerome C. Keller.................................................. 181,000 (11) 1.22%
Peter L. Buzy..................................................... 46,000 (12) *
Jules Blake, Ph.D................................................. 31,455 (13) *
Ann L. Johnson, M.D............................................... 28,500 (14) *
Gordon S. Macklin................................................. 71,143 (15) *
Douglas J. MacMaster.............................................. 38,500 (16) *
John H. Mahar..................................................... 29,350 (17) *
Sandra Panem, Ph.D................................................ 33,000 (18) *
Eugene H. Rotberg................................................. 70,250 (19) *
</TABLE>
<PAGE> 9
<TABLE>
<S> <C> <C>
William D. Smart.................................................. 67,000 (20) *
All Executive Officers and Directors
as a group (15 persons)........................................... 2,238,658 12.64%
</TABLE>
- --------------------
* Less than one percent.
(1) Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or
investment power with respect to securities. Shares of Common Stock
subject to options or warrants currently exercisable or exercisable within
60 days of January 20, 2000 are deemed outstanding for purposes of
computing the percentage ownership of the person holding such option or
warrant but are not deemed outstanding for purposes of computing the
percentage ownership of any other person. Except where indicated
otherwise, and subject to community property laws where applicable, the
persons named in the table above have sole voting and investment power
with respect to all shares of Common Stock shown as beneficially owned by
them.
(2) Includes currently exercisable warrants to purchase 132,903 shares.
(3) Bank America Corporation shares voting and dispositive power with respect
to these shares and Nationsbanc Capital Corporation shares voting and
dispositive power with respect to 972,432 of such shares.
(4) Includes currently exercisable warrants to purchase 116,289 shares.
(5) Includes currently exercisable warrants to purchase 99,677 shares.
(6) Includes currently exercisable options and options exercisable within 60
days of January 20, 2000, to purchase 242,000 shares.
(7) Includes 175,000 shares owned by Dr. Radmer's wife, 225,000 shares owned
by the Radmer Family L.P., and currently exercisable options and options
exercisable within 60 days of January 20, 2000 to purchase 120,000 shares.
Excludes 59,300 shares owned by other members of Dr. Radmer's family, and
Dr. Radmer disclaims beneficial ownership of those shares.
(8) Includes currently exercisable options and options exercisable within 60
days of January 20, 2000 to purchase 125,000 shares.
(9) Includes currently exercisable options and options exercisable within 60
days of January 20, 2000 to purchase 126,100 shares.
(10) Includes currently exercisable options and options exercisable within 60
days of January 20, 2000 to purchase 145,000 shares.
(11) Includes currently exercisable options and options exercisable within 60
days of January 20, 2000 to purchase 178,000 shares.
(12) Consists of currently exercisable options and options exercisable within
60 days of January 20, 2000 to purchase 46,000 shares.
(13) Includes currently exercisable options to purchase 28,500 shares.
(14) Includes currently exercisable options to purchase 27,500 shares.
(15) Includes currently exercisable options to purchase 20,000 shares.
(16) Includes currently exercisable options to purchase 28,500 shares.
(17) Consists of currently exercisable options to purchase 29,350 shares.
(18) Includes currently exercisable options to purchase 27,500 shares.
(19) Includes currently exercisable options to purchase 28,500 shares.
(20) Includes currently exercisable options to purchase 28,500 shares.
<PAGE> 10
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Company has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized on March 23, 2000.
MARTEK BIOSCIENCES CORPORATION
By /s/ Steve Dubin
---------------------------------
Steve Dubin
Senior Vice President of
Business Development,
General Counsel and Secretary
